National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- (-) Comparative Effectiveness (9)
- (-) Diabetes (9)
- Evidence-Based Practice (1)
- Healthcare Costs (1)
- Labor and Delivery (1)
- Maternal Care (1)
- (-) Medication (9)
- Medication: Safety (1)
- Newborns/Infants (1)
- Obesity: Weight Management (1)
- Outcomes (4)
- Patient-Centered Outcomes Research (1)
- Pregnancy (1)
- Quality of Life (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 9 of 9 Research Studies DisplayedBasu A, Sohn MW, Bartle B
Development and validation of the real-world progression in diabetes (RAPIDS) model.
This study investigated the value of using the real-world progression in diabetes (RAPIDS) model to increase medication inherence among Veterans Administration (VA) patients. Over 500,000 patients were tracked in 2003 with a 9-year followup. The model includes predictions as to outcomes and medication adherence and was found to be effective.
AHRQ-funded; HS018542.
Citation: Basu A, Sohn MW, Bartle B .
Development and validation of the real-world progression in diabetes (RAPIDS) model.
Med Decis Making 2019 Feb;39(2):137-51. doi: 10.1177/0272989x18817521..
Keywords: Comparative Effectiveness, Diabetes, Medication
Maruther NM, Tseng E, Huftless S
Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis.
The purpose of this study was to evaluate the comparative effectiveness and safety of monotherapy and selected metformin-based combinations in adults with type 2 diabetes. It found that the evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). AHRQ-funded; 290-201-200007.
AHRQ-funded; 290201200007I.
Citation: Maruther NM, Tseng E, Huftless S .
Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Ann Intern Med 2016 Jun 7;164(11):740-51. doi: 10.7326/m15-2650.
.
.
Keywords: Comparative Effectiveness, Medication, Diabetes, Evidence-Based Practice, Medication: Safety
Camelo Castillo W, Boggess K, Sturmer T
Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes.
The purpose of this study was to estimate the risks of adverse pregnancy outcomes among women receiving glyburide compared with insulin for the treatment of gestational diabetes mellitus (GDM) in a US population-based cohort. It found an association between glyburide (compared with insulin) and elevated risk of NICU admission, neonatal hypoglycemia, respiratory distress, birth injury, and large for gestational age in women with GDM.
AHRQ-funded; HS017950.
Citation: Camelo Castillo W, Boggess K, Sturmer T .
Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes.
JAMA Pediatr 2015 May;169(5):452-8. doi: 10.1001/jamapediatrics.2015.74..
Keywords: Adverse Drug Events (ADE), Adverse Events, Comparative Effectiveness, Diabetes, Labor and Delivery, Maternal Care, Medication, Newborns/Infants, Outcomes, Pregnancy, Women
Romanelli RJ, Chung S, Pu J
Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.
The purpose of this study was to quantify the effectiveness of early versus delayed initiation of metformin monotherapy on glycemic control (measured by change in HbA1c) and weight modification (change in body mass index [BMI]). It found that treatment with metformin earlier in the course of type 2 diabetes is associated with better glycemic control, more pronounced weight reduction, and a lower risk for therapy intensification than delayed treatment.
AHRQ-funded; HS019815.
Citation: Romanelli RJ, Chung S, Pu J .
Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.
Diabetes Res Clin Pract 2015 Apr;108(1):170-8. doi: 10.1016/j.diabres.2014.12.019..
Keywords: Diabetes, Medication, Comparative Effectiveness, Obesity: Weight Management, Outcomes
Prentice JC, Conlin PR, Gellad WF
Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
The researchers compared the effects of neutral protamine Hagedorn (NPH) and long-acting insulin analogues on long-term outcomes. They found no consistent difference in long-term health outcomes when comparing use of long-acting insulin analogues and NPH insulin. The higher cost of analogue insulin without demonstrable clinical benefit raises questions of its cost effectiveness in the treatment of patients with diabetes.
AHRQ-funded; HS019708.
Citation: Prentice JC, Conlin PR, Gellad WF .
Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
Am J Manag Care 2015 Mar;21(3):e235-43..
Keywords: Comparative Effectiveness, Diabetes, Healthcare Costs, Medication, Outcomes
Tan A, Holmes HM, Kuo YF
Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
This study assessed the prevalence of coadministration of co-trimoxazole with sulfonylureas and risk of subsequent emergency room (ER) visits for hypoglycemia among older patients with diabetes. It found that the coadministration of co-trimoxazole with sulfonylureas is associated with increased risk of hypoglycemia. Such coadministration is prevalent among older diabetic patients and varies substantially across U.S. geographic regions.
AHRQ-funded; HS022134.
Citation: Tan A, Holmes HM, Kuo YF .
Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
J Gerontol A Biol Sci Med Sci 2015 Feb;70(2):247-54. doi: 10.1093/gerona/glu072..
Keywords: Comparative Effectiveness, Patient-Centered Outcomes Research, Diabetes, Medication
Prentice JC, Conlin PR, Gellad WF
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
This study used observational quasi-experimental methods using instrumental variables (IVs) to compare the effect of two hypoglycemic medications, sulfonylureas (SUs) and thiazolidinediones (TZDs), on long-term outcomes. It found that individuals who used an SU as a second-line agent experienced significantly more adverse long-term health outcomes than did individuals who started on a TZD.
AHRQ-funded; HS019708.
Citation: Prentice JC, Conlin PR, Gellad WF .
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Value Health 2014 Dec;17(8):854-62. doi: 10.1016/j.jval.2014.08.2674..
Keywords: Diabetes, Medication, Outcomes, Comparative Effectiveness
Zhang Y, McCoy RG, Mason JE
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
The researchers aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. According to the model used by the researchers, all regimens resulted in similar life years and quality-adjusted life years (QALYs) regardless of glycemic control goal, but the regimen with sulfonylurea incurred significantly lower cost per QALY.
AHRQ-funded; HS017628.
Citation: Zhang Y, McCoy RG, Mason JE .
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Diabetes Care 2014;37(5):1338-45. doi: 10.2337/dc13-1901..
Keywords: Diabetes, Comparative Effectiveness, Quality of Life, Medication
Raebel MA, Xu S, Goodrich GK
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
This study sought to identify predictors of initiating any antihyperglycemic medication, and specifically sulfonylurea versus metformin in patients with newly diagnosed with diabetes. Most (59.7 percent) patients with newly diagnosed diabetes did not start any antihyperglycemic medication. Among those who did, metformin was generally the first antihyperglycemic initiated.
AHRQ-funded; HS019859
Citation: Raebel MA, Xu S, Goodrich GK .
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
Ann Pharmacother. 2013 Oct;47(10):1280-91. doi: 10.1177/1060028013503624..
Keywords: Diabetes, Medication, Comparative Effectiveness